QUALITATIVE CONSISTENCY OF TREATMENT EFFECTS IN MULTIREGIONAL CLINICAL TRIALS

被引:6
|
作者
Tanaka, Yoko [1 ]
Li, Gang [2 ]
Wang, Yining [3 ]
Chen, Josh [4 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] LifeScan Inc, W Chester, PA USA
[3] Johnson & Johnson, Titusville, NJ USA
[4] Merck & Co Inc, Rahway, NJ 07065 USA
关键词
False-positive; Multiregional clinical trial; Multivariate likelihood ratio test; Probability for claiming consistency; Qualitative consistency; SAMPLE-SIZE; REGIONS; POINTS; DESIGN;
D O I
10.1080/10543406.2012.703603
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Consistency of treatment effects across different regions in multiregional clinical trials (MRCTs) has been an important question for the regulatory authorities. Many consistency definitions are proposed in literature. One of the definitions of consistency is expressed as qualitative consistency, whereas inconsistency is defined as qualitative treatment by region interaction. This article focuses on the qualitative consistency and extends Gail-Simon and Sasabuchi's one-sided multivariate likelihood ratio tests. Simulations are used to evaluate operating characteristics of these qualitative consistency assessment approaches. For a given number of regions, the guideline for setting significance level, and consistency cut-off are explored.
引用
收藏
页码:988 / 1000
页数:13
相关论文
共 50 条
  • [31] Regional consistency and sample size considerations in a multiregional equivalence trial
    Wu, Si-Cheng
    Xu, Jin-Fang
    Zhang, Xin-Ji
    Li, Zhi-Wei
    He, Jia
    PHARMACEUTICAL STATISTICS, 2020, 19 (06) : 897 - 908
  • [32] Japanese Guideline on Global Clinical Trials: Statistical Implications and Alternative Criteria for Assessing Consistency
    Carroll, Kevin J.
    Le Maulf, Florence
    DRUG INFORMATION JOURNAL, 2011, 45 (05): : 657 - 667
  • [33] MULTIREGIONAL CLINICAL TRIALS: JAPANESE PERSPECTIVE ON DRUG DEVELOPMENT STRATEGY AND SAMPLE SIZE FOR JAPANESE SUBJECTS
    Ando, Yuki
    Uyama, Yoshiaki
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 977 - 987
  • [34] Impact of Different Regulatory Requirements for Trial Endpoints in Multiregional Clinical Trials
    Cynthia J. Girman
    Ekopimo Ibia
    Shailendra Menjoge
    Carmen Mak
    Joshua Chen
    Anupam Agarwal
    Bruce Binkowitz
    Drug information journal : DIJ / Drug Information Association, 2011, 45 : 587 - 594
  • [35] DESIGN AND EVALUATION OF MULTIREGIONAL TRIALS WITH HETEROGENEOUS TREATMENT EFFECT ACROSS REGIONS
    Chen, Chi-Tian
    Hung, H. M. James
    Hsiao, Chin-Fu
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 1037 - 1050
  • [36] ASSESSMENT OF REGIONAL TREATMENT EFFECT IN A MULTIREGIONAL CLINICAL TRIAL
    Tsong, Yi
    Chang, Wan-Jung
    Dong, Xiaoyu
    Tsou, Hsiao-Hui
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 1019 - 1036
  • [37] Results of a Survey of PhRMA Member Companies on Practices Associated with Multiregional Clinical Trials
    Nick Scott
    Bruce Binkowitz
    Ekopimo Okon Ibia
    Tonya Houck
    Belinda Field
    Steven D. Talerico
    Yoko Tanaka
    Andy Lee
    Drug information journal : DIJ / Drug Information Association, 2011, 45 : 609 - 617
  • [38] Results of a Survey of PhRMA Member Companies on Practices Associated With Multiregional Clinical Trials
    Scott, Nick
    Binkowitz, Bruce
    Ibia, Ekopimo Okon
    Houck, Tanya
    Field, Belinda
    Talerico, Steven D.
    Tanaka, Yoko
    Lee, Andy
    DRUG INFORMATION JOURNAL, 2011, 45 (05): : 609 - 617
  • [39] DESIGN AND ANALYSIS ISSUES OF MULTIREGIONAL CLINICAL TRIALS WITH DIFFERENT REGIONAL PRIMARY ENDPOINTS
    Tsou, Hsiao-Hui
    Tsong, Yi
    Chang, Wan-Jung
    Dong, Xiaoyu
    Hsiao, Chin-Fu
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 1051 - 1059
  • [40] An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials
    Huang, Yufen
    Chang, Wan-Jung
    Hsiao, Chin-Fu
    PHARMACEUTICAL STATISTICS, 2013, 12 (02) : 59 - 64